Kaleido Biosciences, an early-stage biotech developing microbiome therapies for rare genetic disorders, announced terms for its IPO on Tuesday.
The Lexington, MA-based company plans to raise $100 million by offering 4.8 million shares at a price range of $20 to $22. At the midpoint of the proposed range, Kaleido Biosciences would command a fully diluted market value of $709 million.
Kaleido Biosciences was founded in 2015 and plans to list on the Nasdaq under the symbol KLDO. Goldman Sachs, J.P. Morgan and Morgan Stanley are the joint bookrunners on the deal. It is expected to price during the week of February 25, 2019.
